Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-02-22
2009-02-03
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387100, C424S178100
Reexamination Certificate
active
07485300
ABSTRACT:
The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
REFERENCES:
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
Daad et al., “97th American Association for Cancer Research Annual Meeting”, Apr. 1-5, 2006, Toronto, Canada, Abstract 637.
Green et al., “Disruption of Cell-Cell Adhesion Enhances Antibody-Dependent Cellular Cytotoxicity: Implications for Antibody-Based Therapeutics of Cancer”, Cancer Research (2002), vol. 62, pp. 6891-6900.
Kohler et al, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”, Nature (Aug. 1975), vol. 256, pp. 495-497.
Liu et al., “Eradication of Large Colon Tumor Xenografts by Targeted Delivery of Maytansinoids”, Proceedings of the National Academy of Sciences of the U.S.A. (1996), vol. 93, pp. 8618-8623.
Mount et al., “Chimeric (Mouse/Human) Anti-Colon Cancer Antibody c30.6 Inhibits the Growth of Human Colorectal Cancer Xenografts in scid/scid Mice”, Cancer Research (1994), vol. 54, pp. 6160-6166.
Cechetto Lisa M.
Findlay Helen P.
Hahn Susan E.
McConkey Fortunata
Sayegh Daad
Arius Research Inc.
Helms Larry R.
McHale & Slavin P.A.
Natarajan Meera
LandOfFree
Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4138092